CDK4 and cancer: In short, although it is now clear that cancer cells can evade immunosurveillance following CDK4/6i treatment through multiple mechanisms, more evidence is needed to demonstrate the universality of the above-mentioned phenomenon and the feasibility of treatment strategies.